TY - JOUR
T1 - Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer
T2 - A subgroup analysis of elderly patients
AU - Nogami, Naoyuki
AU - Nishio, Makoto
AU - Okamoto, Isamu
AU - Enatsu, Sotaro
AU - Suzukawa, Kazumi
AU - Takai, Hiroki
AU - Nakagawa, Kazuhiko
AU - Tamura, Tomohide
N1 - Funding Information:
The authors acknowledge all the patients and investigators who participated in this study. Medical writing support was provided by Gregory Smith (Eli Lilly Japan K.K.). This trial was sponsored by Eli Lilly Japan K.K.
Publisher Copyright:
© 2018 The Japanese Respiratory Society
PY - 2019/1
Y1 - 2019/1
N2 - Background: The combination of pemetrexed and carboplatin is commonly used for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC), mainly because it is comparatively effective and less toxic than other platinum-doublet therapies. Using the JMII (JACAL) study, we report the efficacy and safety of this treatment followed by pemetrexed maintenance in the elderly population (≥70 years of age). Methods: The JMII study was a multicenter, post-marketing study that assessed the efficacy and safety of carboplatin (AUC6) and pemetrexed (500 mg/m 2 , given on Day 1 of a 21-day cycle, 4 cycles) followed by pemetrexed (500 mg/m 2 ) maintenance in advanced non-squamous NSCLC patients (n = 109). Retrospective subgroup analyses were performed in elderly patients aged ≥70. Results: The study includes younger (<70 years, n = 84) and elderly (≥70 years, n = 25) patients who received induction therapy. Median progression-free survival and overall survival from the start of the induction phase were 5.2 (95% CI: 3.5, 8.2) and 16.8 (95% CI: 10.3, NC) months for the elderly patients compared with 5.8 (95% CI: 4.3, 7.4) and 20.5 (95% CI: 16.7, NC) months for the younger patients, respectively. Grade 3/4 hematologic toxicities were more frequent in the elderly patients. Non-hematologic toxicities in the elderly patients were comparable to those in younger patients. Dose reduction was more common in the elderly (44% vs 23%), due to hematologic toxicities. Conclusions: There was no difference in efficacy (evaluated by progression-free survival) between elderly and younger patients. Although grade 3/4 hematologic toxicities were frequently observed in the elderly patients, they were easily managed with dose adjustment.
AB - Background: The combination of pemetrexed and carboplatin is commonly used for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC), mainly because it is comparatively effective and less toxic than other platinum-doublet therapies. Using the JMII (JACAL) study, we report the efficacy and safety of this treatment followed by pemetrexed maintenance in the elderly population (≥70 years of age). Methods: The JMII study was a multicenter, post-marketing study that assessed the efficacy and safety of carboplatin (AUC6) and pemetrexed (500 mg/m 2 , given on Day 1 of a 21-day cycle, 4 cycles) followed by pemetrexed (500 mg/m 2 ) maintenance in advanced non-squamous NSCLC patients (n = 109). Retrospective subgroup analyses were performed in elderly patients aged ≥70. Results: The study includes younger (<70 years, n = 84) and elderly (≥70 years, n = 25) patients who received induction therapy. Median progression-free survival and overall survival from the start of the induction phase were 5.2 (95% CI: 3.5, 8.2) and 16.8 (95% CI: 10.3, NC) months for the elderly patients compared with 5.8 (95% CI: 4.3, 7.4) and 20.5 (95% CI: 16.7, NC) months for the younger patients, respectively. Grade 3/4 hematologic toxicities were more frequent in the elderly patients. Non-hematologic toxicities in the elderly patients were comparable to those in younger patients. Dose reduction was more common in the elderly (44% vs 23%), due to hematologic toxicities. Conclusions: There was no difference in efficacy (evaluated by progression-free survival) between elderly and younger patients. Although grade 3/4 hematologic toxicities were frequently observed in the elderly patients, they were easily managed with dose adjustment.
UR - http://www.scopus.com/inward/record.url?scp=85054191818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054191818&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2018.09.003
DO - 10.1016/j.resinv.2018.09.003
M3 - Article
C2 - 30293944
AN - SCOPUS:85054191818
SN - 2212-5345
VL - 57
SP - 27
EP - 33
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 1
ER -
